From standardization to precision medicine: Evolution of European Leukemianet recommendations in Philadelphia-negative myeloproliferative neoplasms.
The European LeukemiaNet (ELN) recommendations have been instrumental in shaping the diagnosis, risk stratification, and management of Philadelphia-negative myeloproliferative neop. Over the past two decades, these recommendations have evolved from consensus-based frameworks focused on response standardization to increasingly sophisticated, evidence-based and .
The European LeukemiaNet (ELN) recommendations have been instrumental in shaping the diagnosis, risk stratification, and management of Philadelphia-negative myeloproliferative neop. Over the past two decades, these recommendations have evolved from consensus-based frameworks focused on response standardization to increasingly sophisticated, evidence-based and .
What the study was
- Study design
- Clinical Trial
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Leukemia research
Why it surfaced
STANDARD priority (score 7/10); study design: Clinical Trial; topic: Hematologic malignancies; flag: PROMISING_PRELIMINARY
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.